ENGN
enGene Holdings Inc

1,174
Mkt Cap
$677.26M
Volume
94,138.00
52W High
$12.25
52W Low
$2.65
PE Ratio
-4.41
ENGN Fundamentals
Price
$10.00
Prev Close
$10.11
Open
$9.72
50D MA
$9.48
Beta
0.43
Avg. Volume
431,987.95
EPS (Annual)
-$2.29
P/B
3.14
Rev/Employee
$0.00
$206.55
Loading...
Loading...
News
all
press releases
enGene (ENGN) Expected to Announce Earnings on Monday
enGene (NASDAQ:ENGN) will be releasing its Q1 2026 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·15h ago
News Placeholder
More News
News Placeholder
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 31.5% in February
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 1,501,696 shares, a...
MarketBeat·1d ago
News Placeholder
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of "Moderate Buy" by Brokerages
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are presently covering the stock, MarketBeat.com reports...
MarketBeat·2d ago
News Placeholder
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper outlined the company's near-term regulatory and clinical plans for its lead program, detalimogene voraplasmid, during a presentation at...
MarketBeat·3d ago
News Placeholder
enGene to Participate in Upcoming Investor Conferences
enGene Holdings Inc. (Nasdaq: ENGN or enGene), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences...
Business Wire·10d ago
News Placeholder
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 52.2% in January
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 2,192,033...
MarketBeat·16d ago
News Placeholder
enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment
enGene (NASDAQ:ENGN) CEO Ron Cooper said the company's lead product candidate, detalimogene, is being developed with an eye toward the practical needs of urologists treating high-risk non-muscle...
MarketBeat·19d ago
News Placeholder
enGene (NASDAQ:ENGN) Shares Gap Up - Here's What Happened
enGene (NASDAQ:ENGN) Shares Gap Up - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Jefferies Financial Group Initiates Coverage on enGene (NASDAQ:ENGN)
Jefferies Financial Group assumed coverage on shares of enGene in a report on Friday. They set a "buy" rating and a $28.00 target price for the company...
MarketBeat·1mo ago
News Placeholder
enGene (NASDAQ:ENGN) Shares Down 5.7% - Here's Why
enGene (NASDAQ:ENGN) Trading Down 5.7% - Here's Why...
MarketBeat·1mo ago
<
1
2
...
>

Latest ENGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.